Poor Novo Nordisk. The Danish Big Pharma company said on Wednesday more data is needed on NovoSeven, recombinant human coagulation Factor VIIa (rFVIIa), after researchers linked the anti-bleeding medicine to deaths and strokes.
A report in the Journal of the American Medical Association published on Wednesday said NovoSeven has been linked to 67 deaths since it was approved in 1999 as a hemophilia treatment.
Insiders' view: this may well affect approval for any possible future indications for the drug, such as cerebral haemorrhage.
Reuters
No comments:
Post a Comment